LakeShore Biopharma Co. L... (LSB)
NASDAQ: LSB
· Real-Time Price · USD
0.79
0.00 (0.00%)
At close: Aug 15, 2025, 3:59 PM
0.79
0.00%
After-hours: Aug 15, 2025, 04:00 PM EDT
LakeShore Biopharma Ltd Income Statement
Financials in CNY. Fiscal
year is
April - March.
| Fiscal Year | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
Revenue | 135.53M | 168.71M | 96.82M | 176.27M | 106.12M | 180.46M | 194.79M | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 101.12M | 34.9M | 17.51M | 34.68M | 21.15M | 38.27M | 42.73M | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 34.41M | 133.81M | 79.31M | 141.59M | 84.96M | 142.19M | 152.06M | n/a | n/a | n/a | n/a | n/a |
Operating Income | -181.15M | -84.16M | -113.2M | -70.05M | -73.5M | -47.8M | -5.92M | -2.75M | -1.48M | -1.92M | -1.31M | -260.75K |
Interest Income | n/a | 30.77K | 1.96M | n/a | n/a | 6.75M | 7.6M | 1.81M | 127.93K | 26.9K | 16.6K | 3.08K |
Pretax Income | -194.9M | -87.6M | -105.22M | -70.13M | -111.67M | -87.56M | -29.3M | 11.52M | 45.27M | 19.74M | 6.68M | -30.24M |
Net Income | -181.41M | -80.15M | -104.98M | -69.54M | -111.07M | -52.74M | 8.5M | 11.52M | 45.27M | 19.74M | 6.68M | -30.24M |
Selling & General & Admin | 62.6M | 149.72M | 114.3M | 111.01M | 46.26M | 95.87M | 100.99M | 2.75M | 1.48M | 1.92M | 1.31M | 260.74K |
Research & Development | 58.81M | 68.24M | 78.21M | 100.64M | 96.99M | 97.3M | 53.77M | n/a | n/a | n/a | n/a | n/a |
Other Expenses | 94.14M | n/a | -381.93K | -213K | 15.21M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 215.55M | 217.96M | 179.36M | 210.17M | 158.46M | 223M | 173.76M | 2.75M | 1.48M | 1.92M | 1.31M | 260.74K |
Interest Expense | 23.64M | 8.35M | 6.9M | 8.03M | n/a | n/a | 54.09M | 49.42M | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | 72.08M | 71.34M | 78.51M | 79.19M | 48.51M | 73.75M | 80.03M | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 316.67M | 252.86M | 196.87M | 244.85M | 179.62M | 261.27M | 216.48M | 2.75M | 1.48M | 1.92M | 1.31M | 260.74K |
Income Tax Expense | -13.72M | -7.45M | -234.35K | -586K | 598.06K | 1.16M | 46.55K | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 99.99M | 93.06M | 93.06M | 93.06M | 85.24M | 61.79M | 61.74M | 25.75M | 25.75M | 29.5M | 29.5M | 28.75M |
Shares Outstanding (Diluted) | 99.99M | 93.06M | 93.06M | 93.06M | 85.24M | 61.79M | 61.74M | 25.75M | 25.75M | 29.5M | 29.5M | 28.75M |
EPS (Basic) | -1.81 | -0.85 | -1.13 | -0.75 | -1.3 | -0.82 | 0.14 | 0.45 | 1.78 | 0.70 | 0.23 | -1.03 |
EPS (Diluted) | -1.81 | -0.85 | -1.13 | -0.75 | -1.3 | -0.82 | 0.14 | 0.45 | 1.78 | 0.70 | 0.23 | -1.03 |
EBITDA | -82.62M | -72.35M | -98.48M | -62.1M | -55.65M | -40.06M | 114.23M | -2.75M | -1.48M | -1.92M | -1.31M | -260.75K |
EBIT | -93.16M | -11.51M | -98.32M | -62.1M | -9.43M | -6.98M | 5.71M | -11.61M | -4.95M | 3.1M | 1.03M | -4.68M |
Depreciation & Amortization | 10.55M | 9.15M | 14.73M | 1.26M | 9.18M | 7.74M | 8.65M | n/a | n/a | n/a | n/a | n/a |